Depression, Anxiety During Pregnancy Associated with Significant Increase in Adverse Perinatal Outcomes
Diagnosis of a mood or anxiety disorder during pregnancy was associated with a 3.5-fold increase in adverse perinatal outcomes.
Diagnosis of a mood or anxiety disorder during pregnancy was associated with a 3.5-fold increase in adverse perinatal outcomes.
Largest studies to date demonstrate statistically significant risk of preterm birth among women with active PTSD.
Peer support interventions can reduce the incidence of postpartum depression and the severity of depressive symptoms.
All of our information on the reproductive safety of medications comes from non-randomized studies. However, many of these studies fail to take into consideration other factors associated with maternal psychiatric illness which may also affect outcomes.
The use of valproic acid during pregnancy is associated with a significant increase in risk of major malformations and neurodevelopmental disorders. Given these risks, should it be a treatment option for women of childbearing age?
A recent review and meta-analysis found that upwards of 20% of women with no history of psychiatric illness experience their first bipolar-spectrum mood episode during the perinatal period.
Maternal ACEs were associated with both newborn amygdala volume and subsequent infant negative emotionality.
A recent study shows the OCRDs, especially those that are more body-focused, have the potential to emerge or worsen during pregnancy and the postpartum, leading to high levels of comorbid depression and functional impairment.
Despite the unequivocal benefits of folic acid supplementation and recommendations urging all women of reproductive age to take folic acid supplements, preconceptual use of folic acid has not increased substantially.
This task force does not recommend universal, instrument-based screening for perinatal depression because we lack clear evidence that screening improves outcomes.